https://www.nasdaq.com/press-release/biomarin-to-participate-in-two-virtual-investor-conferences-in-january-2022-01-04
https://www.nasdaq.com/press-release/biomarin-and-skyline-therapeutics-announce-strategic-collaboration-to-develop-novel
https://www.nasdaq.com/press-release/biomarin-appoints-former-ceo-of-celgene-corporation-mark-alles-to-board-of-directors
https://www.nasdaq.com/press-release/biomarin-to-hold-virtual-rd-day-at-11%3a00am-et-today-2021-11-30
https://www.nasdaq.com/press-release/biomarin-to-participate-in-two-upcoming-virtual-investor-conferences-2021-11-29
https://www.nasdaq.com/press-release/biomarin-receives-fda-approval-for-voxzogotm-vosoritide-for-injection-indicated-to
https://www.nasdaq.com/press-release/entos-and-biomarin-enter-into-agreement-for-product-candidates-incorporating-entos
https://www.nasdaq.com/press-release/biomarin-announces-third-quarter-2021-financial-results-and-corporate-updates-2021-10
https://www.nasdaq.com/press-release/biomarin-to-participate-in-four-upcoming-virtual-investor-conferences-2021-10-25
https://www.nasdaq.com/press-release/biomarin-to-host-third-quarter-2021-financial-results-conference-call-and-webcast-on
https://www.nasdaq.com/press-release/biomarin-hires-industry-veterans-to-fill-key-roles-in-rd-and-technical-operations
https://www.nasdaq.com/press-release/u.s.-fda-placed-a-clinical-hold-on-bmn-307-phearless-phase-1-2-gene-therapy-study-in
https://www.nasdaq.com/press-release/european-commission-approves-biomarins-voxzogor-vosoritide-for-the-treatment-of-0
https://www.nasdaq.com/press-release/european-commission-approves-biomarins-voxzogor-vosoritide-for-the-treatment-of
https://www.nasdaq.com/press-release/biomarin-to-participate-in-three-upcoming-virtual-investor-conferences-2021-08-25
https://www.nasdaq.com/press-release/biomarin-announces-second-quarter-2021-financial-results-and-corporate-updates-2021
https://www.nasdaq.com/press-release/biomarin-announces-oral-presentation-at-international-society-on-thrombosis-and
https://www.nasdaq.com/press-release/biomarin-announces-oral-presentation-of-positive-one-year-results-from-phase-3
https://www.nasdaq.com/press-release/european-medicines-agency-validates-biomarins-marketing-authorization-application-0
https://www.nasdaq.com/press-release/biomarin-to-host-second-quarter-2021-financial-results-conference-call-and-webcast-on
https://www.nasdaq.com/press-release/biomarin-announces-12-presentations-at-the-international-society-on-thrombosis-and
https://www.nasdaq.com/press-release/biomarin-resubmits-marketing-authorization-application-maa-to-european-medicines
https://www.nasdaq.com/press-release/biomarin-receives-positive-chmp-opinion-in-europe-for-vosoritide-for-the-treatment-of
https://www.nasdaq.com/press-release/biomarin-to-participate-in-the-virtual-bofa-securities-2021-napa-biopharma-conference
https://www.nasdaq.com/press-release/biomarin-to-participate-in-two-upcoming-virtual-investor-conferences-2021-05-27
https://www.nasdaq.com/press-release/european-medicines-agency-grants-biomarins-request-for-accelerated-assessment-of
https://www.nasdaq.com/press-release/biomarin-provides-highlights-of-5-years-of-clinical-data-from-ongoing-phase-1-2-study
https://www.nasdaq.com/press-release/biomarin-to-participate-in-two-upcoming-virtual-investor-conferences-2021-05-18
https://www.nasdaq.com/press-release/biomarin-announces-6-presentations-at-american-society-of-gene-and-cell-therapy-asgct
https://www.nasdaq.com/press-release/biomarin-to-participate-in-two-upcoming-virtual-investor-conferences-2021-05-03
https://www.nasdaq.com/press-release/biomarin-announces-first-quarter-2021-financial-results-and-corporate-updates-2021-04
https://www.nasdaq.com/press-release/allen-institute-and-biomarin-team-up-to-develop-gene-therapies-for-rare-brain
https://www.nasdaq.com/press-release/biomarin-announces-new-and-updated-data-at-2021-american-college-of-medical-genetics
https://www.nasdaq.com/press-release/biomarin-to-host-first-quarter-2021-financial-results-conference-call-and-webcast-on
https://www.nasdaq.com/press-release/biomarin-announces-oral-presentation-at-endo2021-the-endocrine-societys-annual
https://www.nasdaq.com/press-release/biomarin-announces-fda-regenerative-medicine-advanced-therapy-rmat-designation
https://www.nasdaq.com/press-release/biomarin-completes-full-enrollment-in-phase-2-study-of-vosoritide-for-treatment-of
https://www.nasdaq.com/press-release/biomarin-announces-fourth-quarter-and-record-full-year-2020-financial-results-and
https://www.nasdaq.com/press-release/biomarin-to-participate-in-four-upcoming-virtual-investor-conferences-2021-02-24
https://www.nasdaq.com/press-release/biomarin-appoints-former-goldman-sachs-partner-and-life-sciences-executive-maykin-ho
https://www.nasdaq.com/press-release/biomarin-earns-top-marks-in-human-rights-campaigns-2021-corporate-equality-index-2021
https://www.nasdaq.com/press-release/biomarin-to-host-fourth-quarter-and-full-year-2020-financial-results-conference-call
https://www.nasdaq.com/press-release/biomarin-announces-positive-phase-3-gene-therapy-trial-results-in-adults-with-severe
https://www.nasdaq.com/press-release/biomarin-to-participate-in-two-upcoming-virtual-investor-conferences-2021-01-05
https://www.nasdaq.com/press-release/biomarin-announces-benefit-maintained-for-over-two-years-in-children-with
https://www.nasdaq.com/press-release/biomarin-to-participate-in-two-upcoming-virtual-investor-conferences-2020-12-01
https://www.nasdaq.com/press-release/biomarin-and-deep-genomics-to-collaborate-on-advancing-programs-identified-using
https://www.nasdaq.com/press-release/biomarin-to-participate-in-three-upcoming-virtual-investor-conferences-2020-11-12
https://www.nasdaq.com/press-release/biomarin-expands-vosoritide-clinical-program-2020-11-09
https://www.nasdaq.com/press-release/biomarin-announces-third-quarter-2020-total-revenues-of-%24477-million-2020-11-05
https://www.nasdaq.com/press-release/biomarin-to-participate-in-the-credit-suisse-29th-annual-virtual-healthcare
https://www.nasdaq.com/press-release/food-and-drug-administration-accepts-biomarins-new-drug-application-for-vosoritide-to
https://www.nasdaq.com/press-release/biomarin-to-host-third-quarter-2020-financial-results-conference-call-and-webcast-on
https://www.nasdaq.com/press-release/biomarin-pioneer-in-rare-disease-treatments-for-phenylketonuria-pku-receives-fda
https://www.nasdaq.com/press-release/scientific-luminary-and-macarthur-fellowship-winner-kevin-eggan-ph.d.-joins-biomarin
https://www.nasdaq.com/press-release/biomarin-pioneer-in-phenylketonuria-pku-and-gene-therapy-receives-fda-fast-track
https://www.nasdaq.com/press-release/biomarin-to-participate-in-upcoming-virtual-investor-conference-2020-09-29
https://www.nasdaq.com/press-release/biomarin-pioneer-in-phenylketonuria-pku-and-gene-therapy-doses-first-participant-in
https://www.nasdaq.com/press-release/biomarin-to-participate-in-four-upcoming-virtual-investor-conferences-2020-09-15
https://www.nasdaq.com/press-release/biomarin-announces-presentation-of-vosoritide-phase-3-data-in-children-with
https://www.nasdaq.com/press-release/biomarin-announces-the-lancet-publishes-detailed-vosoritide-phase-3-data
https://www.nasdaq.com/press-release/biomarin-to-participate-in-two-upcoming-virtual-investor-conferences-2020-09-08
https://www.nasdaq.com/press-release/biomarin-submits-new-drug-application-to-u.s.-food-and-drug-administration-for
https://www.nasdaq.com/press-release/biomarin-receives-complete-response-letter-crl-from-fda-for-valoctocogene
https://www.nasdaq.com/press-release/european-medicines-agency-validates-biomarins-marketing-authorization-application-for
https://www.nasdaq.com/press-release/biomarin-to-participate-in-two-upcoming-virtual-investor-conferences-2020-08-10
https://www.nasdaq.com/press-release/biomarin-announces-second-quarter-2020-total-revenue-growth-of-11-to-%24430-million
https://www.nasdaq.com/press-release/biomarin-submits-marketing-authorization-application-to-european-medicines-agency-0
https://www.nasdaq.com/press-release/biomarin-to-host-second-quarter-2020-financial-results-conference-call-and-webcast-on
https://www.nasdaq.com/press-release/biomarin-promotes-company-veteran-brian-r.-mueller-to-executive-vice-president-cfo
https://www.nasdaq.com/press-release/biomarin-to-participate-in-the-virtual-bofa-securities-2020-napa-biopharma-conference
https://www.nasdaq.com/press-release/biomarin-provides-additional-data-from-recent-4-year-update-of-ongoing-phase-1-2
https://www.nasdaq.com/press-release/biomarin-to-participate-in-two-upcoming-virtual-investor-conferences-2020-06-03
https://www.nasdaq.com/press-release/biomarin-provides-highlights-of-4-years-of-clinical-data-from-ongoing-phase-1-2-study
https://www.nasdaq.com/press-release/biomarin-announces-closing-of-exercise-by-initial-purchasers-of-option-to-purchase-an
https://www.nasdaq.com/press-release/biomarin-announces-pricing-of-upsized-%24550-million-senior-subordinated-convertible
https://www.nasdaq.com/press-release/biomarin-announces-proposed-private-offering-of-%24500-million-of-senior-subordinated
https://www.nasdaq.com/press-release/biomarin-to-participate-in-two-upcoming-virtual-investor-conferences-2020-05-06
https://www.nasdaq.com/press-release/biomarin-extends-gene-therapy-leadership-with-dinaqor-in-a-preclinical-collaboration
https://www.nasdaq.com/press-release/biomarin-announces-first-quarter-2020-total-revenue-growth-of-25-to-%24502-million-2020
https://www.nasdaq.com/press-release/biomarin-updates-timing-of-first-quarter-2020-financial-results-conference-call-and
https://www.nasdaq.com/press-release/biomarin-appoints-global-pharmaceutical-veteran-c.-greg-guyer-ph.d.-to-chief
https://www.nasdaq.com/press-release/biomarin-to-host-first-quarter-2020-financial-results-conference-call-and-webcast-on
https://www.nasdaq.com/press-release/biomarin-plans-regulatory-submissions-for-marketing-authorization-of-vosoritide-to
https://www.nasdaq.com/press-release/biomarins-brinda-balakrishnan-m.d.-ph.d.-honored-with-2020-40-under-40-award-from-the
https://www.nasdaq.com/press-release/biomarin-announces-fourth-quarter-and-record-full-year-2019-financial-results-2020-02
https://www.nasdaq.com/press-release/biomarins-biologics-license-application-for-valoctocogene-roxaparvovec-accepted-for
https://www.nasdaq.com/press-release/biomarin-to-participate-in-two-upcoming-investor-conferences-2020-02-12
https://www.nasdaq.com/press-release/biomarin-announces-cfo-succession-2020-02-03
https://www.nasdaq.com/press-release/biomarin-to-host-fourth-quarter-and-full-year-2019-financial-results-conference-call
https://www.nasdaq.com/press-release/biomarin-pioneer-in-phenylketonuria-to-begin-clinical-trial-with-bmn-307-gene-therapy
https://www.nasdaq.com/press-release/biomarin-to-participate-in-goldman-sachs-12th-annual-healthcare-ceos-unscripted%3a-a
https://www.nasdaq.com/press-release/behind-the-seizurer-program-further-expands-access-to-genetic-testing-for-children-to
https://www.nasdaq.com/press-release/biomarin-to-present-at-38th-annual-j.p.-morgan-healthcare-conference-in-san-francisco
https://www.nasdaq.com/press-release/biomarin-announces-new-england-journal-of-medicine-publishes-3-years-of-follow-up
https://www.nasdaq.com/press-release/biomarin-announces-positive-final-results-from-placebo-controlled-phase-3-data-in
https://www.nasdaq.com/press-release/biomarin-submits-marketing-authorization-application-to-european-medicines-agency-for
https://www.nasdaq.com/press-release/poised-for-significant-growth-and-profitability-biomarin-shares-company-highlights
https://www.nasdaq.com/press-release/biomarin-announces-cumulative-additional-height-gain-of-9.0-cm-over-54-months-versus
https://www.nasdaq.com/press-release/biomarin-to-participate-in-jefferies-london-healthcare-conference-on-november-21-2019
https://www.nasdaq.com/press-release/biomarin-to-highlight-innovative-development-pipeline-at-rd-day-on-november-14th-2019
https://www.nasdaq.com/press-release/biomarin-to-host-third-quarter-2019-financial-results-conference-call-and-webcast-on
https://www.nasdaq.com/press-release/biomarin-promotes-lon-cardon-ph.d.-to-chief-scientific-strategy-officer-2019-10-07
https://www.nasdaq.com/press-release/biomarin-to-participate-in-jefferies-gene-therapy-editing-summit-on-october-8-2019-in
https://www.nasdaq.com/press-release/biomarin-to-participate-in-morgan-stanley-17th-annual-global-healthcare-conference-0
https://www.nasdaq.com/press-release/biomarin-to-participate-in-morgan-stanley-17th-annual-global-healthcare-conference-on
https://www.nasdaq.com/press-release/biomarin-to-host-second-quarter-2019-financial-results-conference-call-and-webcast-on
https://www.nasdaq.com/press-release/biomarin-appoints-pharmaceutical-veteran-and-former-j-j-executive-liz-mckee-anderson
https://www.nasdaq.com/press-release/biomarin-plans-regulatory-submissions-for-marketing-authorization-of-valoctocogene
https://www.nasdaq.com/press-release/biomarin-announces-acceptance-of-late-breaking-abstract-at-the-international-society
https://www.nasdaq.com/press-release/biomarin-earns-milestone-payments-from-pfizer-for-talzennar-talazoparib-for
https://www.nasdaq.com/press-release/biomarin-announces-new-england-journal-of-medicine-publishes-vosoritide-phase-2-study
https://www.nasdaq.com/press-release/biomarin-participate-goldman-sachs-40th-annual-global-healthcare-conference-tuesday
https://www.nasdaq.com/press-release/biomarin-announces-approval-vimizimr-elosulfase-alfa-china-treatment-morquio-syndrome
https://www.nasdaq.com/press-release/biomarin-announces-phase-3-cohort-valoctocogene-roxaparvovec-gene-therapy-study
https://www.nasdaq.com/press-release/biomarin-provides-3-years-clinical-data-ongoing-phase-1/2-study-valoctocogene
https://www.nasdaq.com/press-release/biomarin-host-conference-call-tuesday-may-28-2019-provide-valoctocogene-roxaparvovec
https://www.nasdaq.com/press-release/european-commission-approves-palynziqr-pegvaliase-injection-treatment-phenylketonuria
https://www.nasdaq.com/press-release/forbes-names-biomarin-4th-best-midsize-employer-america-2019-04-17
https://www.nasdaq.com/press-release/biomarin-host-first-quarter-2019-financial-results-conference-call-and-webcast
